K1234

K1234 is a novel hybrid small molecule designed as a cholinesterase inhibitor for the potential treatment of Alzheimer's disease. It is chemically derived from Huperzine A and 7-methoxytacrine (7-MEOTA). In vitro studies indicate that K1234 possesses increased potency in inhibiting acetylcholinesterase compared to its parent compounds. Pharmacokinetic evaluations in mice show that the compound is rapidly absorbed following intraperitoneal administration and undergoes extensive tissue distribution and rapid metabolism, primarily via glucuronidation. Although it crosses the blood-brain barrier, its penetration is relatively limited, reaching approximately one-third of the plasma concentration.